Spero Therapeutics, Inc.
SPROSpero Therapeutics, Inc. in brief
Spero Therapeutics, Inc. is a listed company in the Biotechnology industry, based in Cambridge, Massachusetts, USA. It was founded in 2013. Its market value was $69 M on 13 October 2026, which makes it the 20,150th largest listed company in the world and the 3,719th largest in the USA on this site. In the year to December 2025 it had sales of $67 M and a net profit of $9 M, about 13 cents of profit for every dollar of sales. It employs about 146 people. Its largest product and service lines by sales in 2025 were Collaboration revenue - related party (70%), Collaboration revenue (19%) and Grant Revenue (11%). Its shares trade under the symbol SPRO (Nasdaq).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About Spero Therapeutics, Inc.
Spero Therapeutics is a Global, Multi Asset and Clinical Stage Biopharmaceutical company committed to advancing novel treatment approaches for bacterial infections. The company annual revenue is 9.3 million USD as on 2020. The headquarters is in USA.
Spero Therapeutics, Inc. timeline
- 2013
- 🏁· approximateFounded
- 2017
- ✎Renamed Spero Therapeutics, Inc.Formerly Spero Therapeutics, LLC.
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 🔔Initial public offering on NasdaqFinal prospectus filed with the SEC on 2 November 2017; shares registered for exchange trading on 30 October 2017.
- 2023
- 💰Record revenue of $104 millionFY2023, the highest of the 8 years on record.
Events of Spero Therapeutics, Inc. from the company record, SEC EDGAR and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in USA: #3,277 (Jan 2020) · #2,708 (Jan 2021) · #3,091 (Jan 2022) · #4,433 (Dec 2022) · #4,458 (Jul 2023) · #3,855 (Jan 2024) · #1,857 (Mar 2026) · #3,597 (Aug 2026) · #3,700 (Oct 2026)
Key ratios
- P/E ratio
- 8.0×
- Price / sales
- 1.0×
- Price / book
- 1.2×
- Free cash flow yield
- -125.1%
- Net margin
- 12.8%
- Operating margin
- 9.4%
- Return on equity
- 14.5%
- Liabilities / assets
- 14.4%
- Revenue growth
- +39.2%
- R&D / revenue
- 57.6%
- Revenue per employee
- $458 K
- Profit per employee
- $59 K
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $67M | +39.2% | $6M | $9M | 12.8% |
| Dec 2024 | $48M | -53.8% | $-73M | $-69M | -142.9% |
| Dec 2023 | $104M | +93.9% | $21M | $23M | 22.0% |
| Dec 2022 | $54M | +193.0% | $-42M | $-46M | -86.8% |
| Dec 2021 | $18M | +95.7% | $-88M | $-90M | -491.8% |
| Dec 2020 | $9M | -48.6% | $-79M | $-78M | -839.2% |
| Dec 2019 | $18M | +357.2% | $-63M | $-61M | -335.5% |
| Dec 2018 | $4M | — | $-43M | $-42M | -1050.4% |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2025 | $-13M | — | — | $0.15 | — |
| Dec 2024 | $-23M | — | — | $-1.27 | — |
| Dec 2023 | $-33M | — | — | $0.43 | — |
| Dec 2022 | $-8M | — | — | $-1.23 | — |
| Dec 2021 | $-64M | — | — | $-2.91 | — |
| Dec 2020 | $-86M | $0M | $-86M | $-3.52 | — |
| Dec 2019 | $-50M | $0M | $-50M | $-3.35 | — |
| Dec 2018 | $-40M | $2M | $-42M | $-2.60 | — |
Quarterly results
Latest quarter to Sep 2026: revenue —, net income $-44M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.
SEC filings
- Nov 12, 20268-KCurrent reportResults of operations
- Nov 12, 202610-QQuarterly report · period to Sep 2026
- Nov 10, 20268-KCurrent reportDirectors or officers changed
- Oct 27, 20268-KCurrent reportDirectors or officers changed
- Aug 28, 20268-KCurrent reportMaterial agreement · Other events
- Aug 12, 20268-KCurrent reportResults of operations
- Aug 12, 202610-QQuarterly report · period to Jun 2026
- Jul 14, 20268-KCurrent reportMaterial agreement · New financial obligation · Regulation FD disclosure · Other events
- Jun 25, 20268-KCurrent reportDirectors or officers changed · Bylaws amended · Shareholder vote
- Jun 22, 20268-KCurrent reportRegulation FD disclosure · Other events
- May 13, 202610-QQuarterly report · period to Mar 2026
- May 13, 20268-KCurrent reportResults of operations
Official filings of Spero Therapeutics, Inc. with the US Securities and Exchange Commission.
Annual results
- Revenue
- $67 M
- Operating income
- $6 M
- Net income
- $9 M
For year ending December-2025 · source: SEC filing
Balance sheet
- Total assets
- $69 M
- Total liabilities
- $10 M
- Total equity
- $59 M
As of December-2025
Top 61 institutional investors in Spero Therapeutics, Inc.#
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 1 | GSK plc | 9,190,606 | 0 (0.00%) | 15.77% | $11 M | Nov 5, 2026 |
| 2 | Pfizer Inc | 2,362,348 | 0 (0.00%) | 4.05% | $3 M | Nov 12, 2026 |
| 3 | Vanguard Capital Management LLC | 2,036,226 | 0 (0.00%) | 3.49% | $2 M | Nov 13, 2026 |
| 4 | Mackenzie Financial Corp | 1,831,254 | New | 3.14% | $2 M | Nov 2, 2026 |
| 5 | Renaissance Technologies LLC | 1,409,783 | +461,879 (+48.73%) | 2.42% | $2 M | Nov 12, 2026 |
| 6 | Affinity Asset Advisors, LLC | 1,300,000 | New | 2.23% | $2 M | Nov 13, 2026 |
| 7 | Arrowstreet Capital, Limited Partnership | 997,123 | +664,153 (+199.46%) | 1.71% | $1 M | Nov 13, 2026 |
| 8 | Verdad Advisers, LP | 805,702 | +754,367 (+1469.50%) | 1.38% | $1 M | Nov 16, 2026 |
| 9 | Raymond James Financial Inc | 755,633 | +233,928 (+44.84%) | 1.30% | $1 M | Nov 12, 2026 |
| 10 | Citadel Advisors LLC | 725,988 | New | 1.25% | $1 M | Nov 16, 2026 |
| 11 | BlackRock, Inc. | 594,258 | -146 (-0.02%) | 1.02% | $1 M | Nov 13, 2026 |
| 12 | Geode Capital Management, LLC | 499,271 | -67,058 (-11.84%) | 0.86% | $1 M | Nov 6, 2026 |
| 13 | Vanguard Fiduciary Trust Co | 287,648 | 0 (0.00%) | 0.49% | $0 M | Nov 13, 2026 |
| 14 | Two Sigma Investments, LP | 267,195 | -115,619 (-30.20%) | 0.46% | $0 M | Nov 16, 2026 |
| 15 | Morgan Stanley | 258,645 | +257,731 (+28198.14%) | 0.44% | $0 M | Nov 13, 2026 |
| 16 | State Street Corp | 251,251 | +36,500 (+17.00%) | 0.43% | $0 M | Nov 12, 2026 |
| 17 | HRT Financial LP | 204,964 | New | 0.35% | $0 M | Nov 13, 2026 |
| 18 | Prudential Financial Inc | 204,663 | +194,263 (+1867.91%) | 0.35% | $0 M | Nov 16, 2026 |
| 19 | Susquehanna International Group, LLP | 201,937 | -557,353 (-73.40%) | 0.35% | $0 M | Nov 16, 2026 |
| 20 | Marshall Wace, LLP | 195,416 | New | 0.34% | $0 M | Nov 13, 2026 |
| 21 | Shay Capital LLC | 166,030 | +93,639 (+129.35%) | 0.28% | $0 M | Nov 16, 2026 |
| 22 | Invesco Ltd. | 165,530 | +101,285 (+157.65%) | 0.28% | $0 M | Nov 12, 2026 |
| 23 | Employees Retirement System of Texas | 125,081 | New | 0.21% | $0 M | Nov 10, 2026 |
| 24 | Northern Trust Corp | 108,274 | 0 (0.00%) | 0.19% | $0 M | Nov 16, 2026 |
| 25 | XTX Topco Ltd | 104,323 | +53,787 (+106.43%) | 0.18% | $0 M | Nov 16, 2026 |
Show all 61: investors 26 to 61
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 26 | Squarepoint Ops LLC | 94,478 | New | 0.16% | $0 M | Nov 9, 2026 |
| 27 | Dimensional Fund Advisors LP | 91,287 | -183,533 (-66.78%) | 0.16% | $0 M | Nov 4, 2026 |
| 28 | Bridgeway Capital Management, LLC | 63,741 | -51,059 (-44.48%) | 0.11% | $0 M | Nov 16, 2026 |
| 29 | Empowered Funds, LLC | 63,741 | New | 0.11% | $0 M | Nov 13, 2026 |
| 30 | StoneX Group Inc. | 38,241 | New | 0.07% | $0 M | Nov 3, 2026 |
| 31 | Simplex Trading, LLC | 36,830 | -24,482 (-39.93%) | 0.06% | $0 M | Nov 4, 2026 |
| 32 | Panagora Asset Management Inc | 32,762 | New | 0.06% | $0 M | Nov 12, 2026 |
| 33 | Two Sigma Securities, LLC | 32,684 | +22,108 (+209.04%) | 0.06% | $0 M | Nov 16, 2026 |
| 34 | Capital Asset Advisory Services LLC | 32,548 | 0 (0.00%) | 0.06% | $0 M | Oct 30, 2026 |
| 35 | Three Seasons Wealth, LLC | 30,000 | 0 (0.00%) | 0.05% | $0 M | Nov 3, 2026 |
| 36 | Charles Schwab Investment Management Inc | 28,565 | 0 (0.00%) | 0.05% | $0 M | Nov 16, 2026 |
| 37 | Oppenheimer & Co Inc | 26,750 | +3,900 (+17.07%) | 0.05% | $0 M | Oct 26, 2026 |
| 38 | Vanguard Global Advisers, LLC | 25,446 | 0 (0.00%) | 0.04% | $0 M | Nov 13, 2026 |
| 39 | FNY Investment Advisers, LLC | 21,300 | +13,000 (+156.63%) | 0.04% | $0 M | Oct 16, 2026 |
| 40 | O'shaughnessy Asset Management, LLC | 20,704 | New | 0.04% | $0 M | Nov 12, 2026 |
| 41 | Ritholtz Wealth Management | 20,704 | New | 0.04% | $0 M | Nov 5, 2026 |
| 42 | Jane Street Group, LLC | 20,185 | -137,912 (-87.23%) | 0.03% | $0 M | Nov 12, 2026 |
| 43 | Assenagon Asset Management S.A. | 17,762 | -19,510 (-52.34%) | 0.03% | $0 M | Oct 15, 2026 |
| 44 | Rangeley Capital, LLC | 17,202 | New | 0.03% | $0 M | Nov 16, 2026 |
| 45 | UBS Group AG | 16,049 | -123,631 (-88.51%) | 0.03% | $0 M | Nov 10, 2026 |
| 46 | Point72 Asset Management, L.P. | 14,639 | -89,738 (-85.97%) | 0.03% | $0 M | Nov 16, 2026 |
| 47 | Spark Investment Management LLC | 12,300 | New | 0.02% | $0 M | Nov 13, 2026 |
| 48 | Vanguard Personalized Indexing Management, LLC | 11,571 | New | 0.02% | $0 M | Nov 16, 2026 |
| 49 | Torrey Growth & Income Advisors | 11,025 | New | 0.02% | $0 M | Nov 4, 2026 |
| 50 | Jones Financial Companies Lllp | 8,053 | +375 (+4.88%) | 0.01% | $0 M | Nov 13, 2026 |
| 51 | Tower Research Capital LLC (TRC) | 6,838 | New | 0.01% | $0 M | Nov 16, 2026 |
| 52 | Royal Bank Of Canada | 1,936 | -78 (-3.87%) | 0.00% | $0 M | Nov 16, 2026 |
| 53 | FMR LLC | 1,100 | +800 (+266.67%) | 0.00% | $0 M | Nov 10, 2026 |
| 54 | Osaic Holdings, Inc. | 290 | 0 (0.00%) | 0.00% | $0 M | Nov 12, 2026 |
| 55 | Jpmorgan Chase & Co | 236 | 0 (0.00%) | 0.00% | $0 M | Nov 12, 2026 |
| 56 | Wells Fargo & Company/mn | 200 | 0 (0.00%) | 0.00% | $0 M | Nov 16, 2026 |
| 57 | Nuveen, LLC | 177 | New | 0.00% | $0 M | Nov 10, 2026 |
| 58 | US Bancorp \de\ | 151 | 0 (0.00%) | 0.00% | $0 M | Nov 5, 2026 |
| 59 | SBI Securities Co., Ltd. | 61 | +48 (+369.23%) | 0.00% | $0 M | Oct 22, 2026 |
| 60 | Farther Finance Advisors, LLC | 10 | 0 (0.00%) | 0.00% | $0 M | Oct 8, 2026 |
| 61 | Barclays PLC | 6 | New | 0.00% | $0 M | Nov 6, 2026 |
Mutual funds holding Spero Therapeutics, Inc.#
| Fund | Shares | Value | Of the company | Of the fund | Change in shares | Report |
|---|---|---|---|---|---|---|
| 🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc. | 1.40 M | $3 M | 2.4% | <0.01% | +13% | Jun 30, 2026 |
| 🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc. | 593,254 | $1 M | 1.0% | <0.01% | +15% | Jun 30, 2026 |
| 🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC | 224,070 | $1 M | 0.38% | <0.01% | +8.0% | May 31, 2026 |
| 🇺🇸 iShares Micro-Cap ETFBlackRock Fund Advisors | 151,203 | $0 M | 0.26% | 0.02% | new | Jun 30, 2026 |
| 🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC | 107,797 | $0 M | 0.19% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC | 67,356 | $0 M | 0.12% | <0.01% | +10% | May 31, 2026 |
| 🇺🇸 Ultra-Small Company Market FundBridgeway Capital Management, LLC | 64,800 | $0 M | 0.11% | 0.10% | no change | Jun 30, 2026 |
| 🇺🇸 Acuitas US Microcap FundAcuitas Investments, LLC | 56,457 | $0 M | 0.10% | 0.11% | — | Jun 30, 2026 |
| 🇺🇸 Omni Small-Cap Value FundBridgeway Capital Management, LLC | 50,000 | $0 M | 0.09% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC | 36,745 | $0 M | 0.06% | <0.01% | +89% | May 31, 2026 |
| 🇺🇸 Dimensional U.S. Small Cap ETFDimensional Fund Advisors LP | 65,997 | $0 M | 0.11% | <0.01% | +314% | Jul 31, 2026 |
| 🇺🇸 Avantis U.S. Small Cap Equity ETFAmerican Century ETF Trust | 22,770 | $0 M | 0.04% | <0.01% | new | May 31, 2026 |
| 🇺🇸 U.S. Micro Cap PortfolioDimensional Fund Advisors LP | 46,660 | $0 M | 0.08% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc. | 24,176 | $0 M | 0.04% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Vanguard Institutional Total Stock Market Index FundThe Vanguard Group, Inc. | 22,820 | $0 M | 0.04% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Schwab Total Stock Market Index FundCharles Schwab Investment Management, Inc. | 28,565 | $0 M | 0.05% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Invesco RAFI US 1500 Small-Mid ETFInvesco Capital Management LLC | 26,957 | $0 M | 0.05% | <0.01% | +112% | Jul 31, 2026 |
| 🇺🇸 Dimensional U.S. Targeted Value ETFDimensional Fund Advisors LP | 25,054 | $0 M | 0.04% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 1290 VT Micro Cap PortfolioEquitable Investment Management Group, LLC | 10,170 | $0 M | 0.02% | 0.01% | new | Jun 30, 2026 |
| 🇺🇸 U.S. Sustainability Targeted Value PortfolioDimensional Fund Advisors LP | 15,413 | $0 M | 0.03% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 Dimensional VA U.S. Targeted Value PortfolioDimensional Fund Advisors LP | 15,128 | $0 M | 0.03% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 U.S. Small Cap PortfolioDimensional Fund Advisors LP | 10,049 | $0 M | 0.02% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 Dimensional US Core Equity 1 ETFDimensional Fund Advisors LP | 7,979 | $0 M | 0.01% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 U.S. Vector Equity PortfolioDimensional Fund Advisors LP | 7,963 | $0 M | 0.01% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 Victory Extended Market Index FundVictory Capital Management Inc. | 4,961 | $0 M | <0.01% | <0.01% | +6.4% | Jul 31, 2026 |
| 🇺🇸 Dimensional U.S. Core Equity 2 ETFDimensional Fund Advisors LP | 4,874 | $0 M | <0.01% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 U.S. Targeted Value PortfolioDimensional Fund Advisors LP | 4,833 | $0 M | <0.01% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 Blackstone Alternative Multi-Strategy FundBlackstone Alternative Investment Advisors LLC | 2,400 | $0 M | <0.01% | <0.01% | −59% | Jun 30, 2026 |
Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 28 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.
Insider trading at Spero Therapeutics, Inc.#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | Esther RajaveluSee Remarks, Director | Sell | -40,851 | $1.040 | $42 K | 946,000 | Form 4 |
| filed | Debra ZackChief Medical Officer | Grant or award10b5-1 plan | +162,311 | — | — | 162,311 | Form 4 |
| filed | Scott Thomas JacksonDirector | Grant or award | +10,000 | — | — | 85,000 | Form 4 |
| filed | Milind DeshpandeDirector | Grant or award | +10,000 | — | — | 101,454 | Form 4 |
| filed | John C. Pottage Jr.Director | Grant or award | +10,000 | — | — | 85,000 | Form 4 |
| filed | Cynthia SmithDirector | Grant or award | +10,000 | — | — | 85,000 | Form 4 |
| filed | Kathleen TregoningDirector | Grant or award | +10,000 | — | — | 85,000 | Form 4 |
| filed | Patrick V.j.j. VinkDirector | Grant or award | +10,000 | — | — | 85,000 | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
Markets and events: Spero Therapeutics, Inc.#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
Trading halts
- 2025-05-28 16:07 UTC, code LUDP, resumed 16:12 UTC
- 2025-05-28 15:18 UTC, code LUDP, resumed 15:23 UTC
- 2025-05-28 14:54 UTC, code LUDP, resumed 14:59 UTC
- 2025-05-28 14:46 UTC, code LUDP, resumed 14:51 UTC
- 2025-05-28 13:46 UTC, code LUDP, resumed 13:51 UTC
Fails to deliver
- : 1,111 shares at $1.18
- : 50,000 shares at $1.26
- : 15,213 shares at $1.22
- : 17 shares at $1.23
- : 742 shares at $1.23
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
Spero Therapeutics, Inc. scorecard#
Passes 14 of the 20 checks that could be worked out: strongest in growth (5 of 6), weakest in financial health (1 of 3). Fiscal year 2025; market cap of Oct 13, 2026.
Valuation4 of 5
- ✓P/E below its peers' median8.0×P/E 8.0× against Biotechnology's median of 17.5×.
- ✓Price to book below its peers' median1.2×Price to book 1.2× against Biotechnology's median of 2.9×.
- ✓Price to sales below its peers' median1.0×Price to sales 1.0× against Biotechnology's median of 8.7×.
- ✗Free cash flow yield above 5%-125.1%Free cash flow is -125.1% of the market value.
- ✓Earnings yield above the 10-year Treasury yield12.5%Earnings yield 12.5% against the 10-year Treasury's 5.15% on 2026-11-13.
- –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
Growth5 of 6
- ✓Revenue grew in the newest year39.2%Revenue up 39.2% in fiscal 2025.
- ✓Revenue up more than 5% a year over three years7.7%7.7% a year over the three years to fiscal 2025.
- ✗Faster growth over three years than its peers' median7.7%7.7% a year against Biotechnology's median of 12.9% (181 companies).
- ✓Earnings per share grew in the newest year0.15 vs -1.27Diluted EPS 0.15 in fiscal 2025 against -1.27 the year before (report's currency).
- ✓Net income higher than five years earlier$9 M$9 M in fiscal 2025 against -$78 M in 2020.
- ✓Revenue rose in at least four of the last five years4 of 5Revenue rose in 4 of the five years to fiscal 2025.
Profitability4 of 5
- ✓Profitable in the newest year$9 MNet income $9 M in fiscal 2025.
- ✗Profitable in each of the last five years2 of 5Profitable in 2 of the five years to fiscal 2025.
- ✓Operating margin above its peers' median9.4%9.4% against Biotechnology's median of -60.5% (243 companies).
- ✓Return on equity above 15%16.3%16.3% in fiscal 2025.
- –Return on invested capital above 10%No return on invested capital on file.
- ✓Operating margin wider than three years earlier9.4%9.4% in fiscal 2025 against -78.9% in 2022.
Financial health1 of 3
- ✓Short-term assets cover short-term liabilities7.6×Current ratio 7.59 at the end of fiscal 2025.
- –Debt below equityDebt or equity is not on file (or equity is negative).
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- –Operating income covers interest five timesInterest expense is not on file.
- ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
- ✗Altman Z-score outside the distress zone-2.71Z-score -2.71 (distress zone) for fiscal 2025.
Shareholder returns0 of 1
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- ✗Share count up no more than 2% in a year9.2%Diluted shares up 9.2% in fiscal 2025.
- –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
- –Free cash flow covers dividends and buybacksCash from operations or capital spending is not on file.
Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Financial analysis, 2025#
Worked out from Spero Therapeutics, Inc.'s statements, beside the median of Biotechnology.
| Ratio | Trend | 2025 | Median of peers |
|---|---|---|---|
| Operating margin | 9.5% | -60.5% | |
| Net margin | 12.8% | -68.9% | |
| Return on equity | 16.3% | -61.0% | |
| Revenue growth, 3 years a year | 7.7% | 12.9% | |
| Revenue growth | 39.2% | 15.8% |
4of 7on the Piotroski tests of financial strength
- Only -147% of net income arrived as cash from operations.
- The share count rose 9.2% in the year.
Spero Therapeutics, Inc.: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to Dec 31, 2025 | FY 2024to Dec 31, 2024 | FY 2023to Dec 31, 2023 | FY 2022to Dec 31, 2022 | FY 2021to Dec 31, 2021 | FY 2020to Dec 31, 2020 | FY 2019to Dec 31, 2019 | FY 2018to Dec 31, 2018 | FY 2017to Dec 31, 2017 | FY 2016to Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||||
| Revenue | 67+39.2%100% | 48−53.8%100% | 104+94.0%100% | 54+193%100% | 18+95.7%100% | 9.3−48.6%100% | 18+358%100% | 4.0+100%100% | 2.0+491%100% | 0.3—100% | |
| Research and development | 38−60.2%57.6% | 97+88.1%202% | 51+8.1%49.6% | 48−26.2%88.9% | 65−3.7%353% | 67+1.9%718% | 66+94.1%362% | 34+3.1%854% | 33+24.8%1661% | 26—7861% | |
| General and administrative | 21−10.7%31.7% | 24−7.2%49.4% | 26−30.0%24.6% | 36−12.5%68.2% | 42+94.5%228% | 21+37.5%230% | 16+21.0%85.9% | 13+18.9%325% | 11+50.1%548% | 7.2—2156% | |
| Operating expenses | 60−50.1%90.5% | 121+47.4%253% | 82−14.0%79.3% | 96−9.9%179% | 106+20.1%582% | 88+8.7%948% | 81+74.0%448% | 47+7.0%1179% | 44+30.3%2209% | 34—10017% | |
| Operating income | 6.3—9.5% | −73−442%−153% | 21—20.7% | −42—−78.9% | −88—−482% | −79—−848% | −63—−348% | −43—−1079% | −42—−2109% | −33—−9917% | |
| Interest and finance income | 2.5−46.9%3.8% | 4.7+20.3%9.9% | 3.9+256%3.8% | 1.1+220%2.1% | 0.3−13.7%1.9% | 0.4−69.8%4.3% | 1.3+20.6%7.3% | 1.1—27.8% | — | — | |
| Other non-operating income (expense) | 2.5−47.5%3.8% | 4.8+22.2%10.0% | 3.9—3.8% | −4.2—−7.9% | −1.8−314%−9.8% | 0.8−63.6%8.9% | 2.3+100%12.6% | 1.1−38.0%28.8% | 1.8+218%93.2% | 0.6—173% | |
| Income before tax | 8.8—13.2% | −69−370%−143% | 25—24.5% | −46—−86.7% | −90—−492% | −78—−839% | −61—−336% | −42—−1050% | −40—−2015% | −33—−9744% | |
| Income tax | 0.3—0.4% | 0−100%0.0% | 2.6—2.5% | 0—0.0% | 0—0.0% | 0—0.0% | 0—0.0% | 0—0.0% | 0—0.0% | 0—0.0% | |
| Net income including minority interests | 8.6—12.8% | −69−401%−143% | 23—22.0% | −46—−86.7% | −90—−492% | −78—−839% | −61—−336% | −42—−1050% | −40—−2015% | −33—−9744% | |
| Minority interests' share of net income | — | — | — | — | — | — | — | — | −1.1—−57.8% | −7.2—−2134% | |
| Net income attributable to shareholders | 8.6—12.8% | −69−401%−143% | 23—22.0% | — | −90—−492% | −78—−839% | −61—−336% | −42r−42—−1051% | −39—−1958% | −25—−7609% | |
| Earnings per share, basic | 0.15—— | -1.27−395%— | 0.43—— | -1.23—— | -2.91—— | -3.52—— | -3.35—— | -2.60—— | -17.82—— | -95.87—— | |
| Earnings per share, diluted | 0.15—— | -1.27−395%— | 0.43—— | -1.23—— | -2.91—— | -3.52—— | -3.35—— | -2.60—— | -17.82—— | -95.87—— | |
| Shares, weighted average (basic) | 56+3.7%— | 54+2.5%— | 53+40.2%— | 38+21.7%— | 31—— | — | — | — | — | — | |
| Shares, weighted average (diluted) | 59+9.3%— | 54+2.0%— | 53+41.0%— | 38+21.7%— | 31+38.0%— | 22+23.3%— | 18+13.5%— | 16+519%— | 2.6+729%— | 0.3—— | |
| Balance sheet | |||||||||||
| Cash and cash equivalents | 40−23.9%58.4% | 53−30.7%47.8% | 76−30.0%41.9% | 109−3.1%87.4% | 113+32.1%65.8% | 85+187%55.5% | 30−12.8%28.0% | 34−61.0%26.4% | 87+746%93.4% | 10—74.9% | |
| Short-term investments | — | — | — | 0−100%0.0% | 34−18.9%19.8% | 42−20.3%27.2% | 52−35.7%49.3% | 81—63.1% | — | — | |
| Other current assets | 0.0r1.6−98.5%0.0% | 1.9−54.3%1.7% | 4.2+23.6%2.3% | 3.4−61.7%2.7% | 8.8+45.6%5.2% | 6.1+25.7%4.0% | 4.8−35.5%4.5% | 7.5+309%5.8% | 1.8+45.9%2.0% | 1.3—9.1% | |
| Current assets | 67−37.3%97.6% | 107−18.2%97.0% | 131+15.5%71.9% | 114−28.1%91.0% | 158+13.5%92.3% | 139+45.8%90.7% | 95−23.2%89.9% | 124+34.9%96.3% | 92+675%98.5% | 12—86.2% | |
| Property, plant and equipment | — | 0−100%0.0% | 0.0−99.5%0.0% | 0.4−64.1%0.3% | 1.0−38.5%0.6% | 1.7−26.6%1.1% | 2.3−21.4%2.1% | 2.9+149%2.2% | 1.2−22.4%1.2% | 1.5—10.9% | |
| Right-of-use (leased) assets | 1.5−52.5%2.1% | 3.1−25.1%2.8% | 4.2−18.9%2.3% | 5.1−21.5%4.1% | 6.5−8.2%3.8% | 7.1+45.9%4.6% | 4.9—4.6% | — | — | — | |
| Total assets | 69−37.7%100% | 111−39.4%100% | 182+46.1%100% | 125−27.0%100% | 171+11.5%100% | 153+44.6%100% | 106−17.8%100% | 129+38.0%100% | 93+579%100% | 14—100% | |
| Accounts payable | 0.7−90.5%1.0% | 7.3+430%6.6% | 1.4+123%0.8% | 0.6−44.0%0.5% | 1.1−4.7%0.6% | 1.2−72.1%0.8% | 4.1+15.1%3.9% | 3.6+3.8%2.8% | 3.5+205%3.7% | 1.1—8.3% | |
| Current liabilities | 8.9−81.9%12.9% | 49+32.1%44.4% | 37+71.6%20.4% | 22+16.0%17.3% | 19+30.2%10.9% | 14−46.2%9.3% | 27+116%25.1% | 12+51.0%9.5% | 8.2+17.9%8.7% | 6.9—50.2% | |
| Lease liabilities (non-current) | 0.9−63.2%1.4% | 2.6−33.3%2.3% | 3.8−22.8%2.1% | 5.0−17.0%4.0% | 6.0−13.3%3.5% | 6.9+49.3%4.5% | 4.6—4.4% | — | — | — | |
| Total liabilities | 9.9−84.6%14.4% | 64−14.7%58.3% | 75+54.5%41.4% | 49−41.0%39.2% | 83+287%48.4% | 21−32.1%14.0% | 32+140%29.7% | 13+54.3%10.2% | 8.5+15.0%9.1% | 7.4—53.8% | |
| Retained earnings | −451—−654% | −460—−416% | −391—−214% | −414—−332% | −367—−215% | −278—−181% | −199—−188% | −139—−107% | −97—−104% | −45—−330% | |
| Shareholders' equity | 59+28.0%85.6% | 46−56.9%41.7% | 107+40.8%58.6% | 76−14.0%60.8% | 88−33.1%51.6% | 132+77.1%86.0% | 75−35.4%70.3% | 116+36.5%89.5% | 85—90.5% | −45—−330% | |
| Minority interests | — | — | — | — | — | — | — | 0.40.0%0.3% | 0.4—0.4% | −3.8—−27.7% | |
| Total equity | — | — | — | — | — | 132+77.1%86.0% | 75−35.6%70.3% | 116+36.4%89.8% | 85—90.9% | −49—−358% | |
| Total liabilities and equity | 69−37.7%100% | 111−39.4%100% | 182+46.1%100% | 125−27.0%100% | 171+11.5%100% | 153+44.6%100% | 106−17.8%100% | 129+38.0%100% | 93+579%100% | 14—100% | |
| Shares outstanding | 56+3.3%— | 55+3.0%— | 53+1.0%— | 52+61.9%— | 32+10.7%— | 29+52.5%— | 19+11.5%— | 17+19.7%— | 14—— | — | |
| Cash-flow statement | |||||||||||
| Depreciation and amortization | 0−100%0.0% | 0.0−99.5%0.0% | 0.4−57.8%0.4% | 0.9+34.5%1.6% | 0.6−15.1%3.5% | 0.8+1.5%8.2% | 0.8+83.4%4.1% | 0.4+12.7%10.3% | 0.4+30.1%18.3% | 0.3—83.3% | |
| Share-based compensation | 4.3−44.5%6.5% | 7.8−1.8%16.2% | 7.9−13.1%7.6% | 9.1−3.3%17.0% | 9.4+92.9%51.7% | 4.9+29.4%52.4% | 3.8+37.4%20.8% | 2.7+92.6%69.3% | 1.4+693%72.1% | 0.2—53.7% | |
| Cash from operating activities | −13—−18.9% | −23—−48.9% | −33—−31.8% | −7.7—−14.4% | −64—−352% | −86—−920% | −50—−276% | −40—−999% | −39—−1976% | −29—−8644% | |
| Capital expenditure | — | — | — | — | — | −0.2—−1.7% | −0.3—−1.7% | −2.4—−61.4% | −0.0—−1.4% | −0.8—−248% | |
| Cash from investing activities | — | — | 0−100%0.0% | 34+341%63.2% | 7.7−26.7%42.0% | 10−64.5%112% | 30—163% | −83—−2097% | −0.0—−1.4% | −0.8—−248% | |
| Shares issued | — | 0−100%0.0% | 0.2—0.2% | — | 7.8−40.5%42.9% | 13−16.6%141% | 16—87.0% | — | — | — | |
| Cash from financing activities | — | 0−100%0.0% | 0.2—0.2% | −30−135%−55.2% | 84−35.8%460% | 131+711%1403% | 16−76.8%88.9% | 70−40.1%1753% | 116+237%5867% | 34—10273% | |
| Change in cash | −13—−18.9% | −23—−48.9% | −33—−31.6% | −3.5−113%−6.5% | 27−50.7%150% | 55—595% | −4.4—−24.0% | −53−169%−1343% | 77+1565%3889% | 4.6—1380% | |
| Report | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the same quarter a year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | Last 12 months4 quarters to Sep 30, 2026 | Q3 FY2026to Sep 30, 2026 | Q2 FY2026to Jun 30, 2026 | Q1 FY2026to Mar 31, 2026 | Q4 FY2025to Dec 31, 2025 | Q3 FY2025to Sep 30, 2025 | Q2 FY2025to Jun 30, 2025 | Q1 FY2025to Mar 31, 2025 | Q4 FY2024to Dec 31, 2024 | Q3 FY2024to Sep 30, 2024 | Q2 FY2024to Jun 30, 2024 | Q1 FY2024to Mar 31, 2024 | Q4 FY2023to Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||||||
| Revenue | 42+2.5%100% | 0−100%— | 0−100%— | 0.3−95.6%100% | 41*+175%100% | 5.4−59.6%100% | 14+39.1%100% | 5.9−36.6%100% | 15*−79.5%100% | 13—100% | 10—100% | 9.3—100% | 74*—100% | |
| Research and development | 15−75.5%36.4% | 3.2−62.8%— | 3.4−67.8%— | 2.9−78.6%1128% | 5.6*−80.6%13.5% | 8.6−68.0%158% | 11−55.0%75.2% | 14−21.5%232% | 29*+74.2%192% | 27—199% | 24—233% | 17—187% | 17*—22.5% | |
| General and administrative | 19−19.0%46.7% | 3.7−10.9%— | 6.5+10.4%— | 4.9−28.4%1894% | 4.3*−39.1%10.4% | 4.2−19.7%76.7% | 5.9+6.2%41.4% | 6.8+15.3%116% | 7.1*+9.7%46.9% | 5.2—38.6% | 5.5—54.3% | 5.9—63.9% | 6.4*—8.7% | |
| Operating expenses | 70−20.4%167% | 42+214%— | 9.9−40.3%— | 7.8−62.2%3022% | 9.9*−73.1%24.0% | 13−58.3%245% | 17−43.2%117% | 21−11.4%351% | 37*+59.9%244% | 32—238% | 29—287% | 23—251% | 23*—31.3% | |
| Operating income | −28—−67.3% | −42—— | −9.9—— | −7.5—−2922% | 31*—76.0% | −7.9—−145% | −2.4—−17.2% | −15—−251% | −22*−143%−144% | −19—−138% | −19—−187% | −14—−151% | 51*—68.7% | |
| Interest and finance income | 2.0−36.8%4.8% | 0.9+71.4%— | 0.4−49.1%— | 0.3−61.1%130% | 0.4*−63.4%0.9% | 0.5−55.0%9.8% | 0.7−38.2%5.2% | 0.9−34.9%14.7% | 1.0*−1.4%6.8% | 1.2—8.8% | 1.2—11.7% | 1.3—14.3% | 1.0*—1.4% | |
| Net interest income | — | 2.4—— | — | — | — | −0.5—−9.8% | — | — | — | — | — | — | — | |
| Other non-operating income (expense) | −1.3−139%−3.1% | −2.4−543%— | 0.4−49.7%— | 0.3−61.3%130% | 0.4*−66.6%0.9% | 0.5−53.8%9.8% | 0.7−37.9%5.2% | 0.9−34.1%14.7% | 1.1*+7.7%7.5% | 1.2—8.6% | 1.2—11.8% | 1.3—14.2% | 1.0*—1.4% | |
| Income tax | — | — | — | — | 0.3*—0.6% | 0−100%0.0% | — | — | −0.3r0.3*−175%−1.9% | 0.3r−0.3—2.2% | — | — | 0.4*—0.5% | |
| Net income including minority interests | −30—−71.0% | −44—— | −9.6—— | −7.2—−2792% | 32*—76.3% | −7.4—−136% | −1.7—−12.0% | −14—−236% | −21*−141%−139% | −17—−127% | −18—−175% | −13—−137% | 51*—69.6% | |
| Net income attributable to shareholders | −30—−71.0% | −44—— | −9.6—— | −7.2—−2792% | 32*—76.3% | −7.4—−136% | −1.7—−12.0% | −14—−236% | −21*−141%−139% | −17—−127% | −18r−18—−175% | −13r−13—−137% | 51*—69.6% | |
| Earnings per share, basic | — | -0.76—— | -0.16—— | -0.13—— | — | -0.13—— | -0.03—— | -0.25—— | — | -0.32—— | -0.33—— | -0.24—— | — | |
| Earnings per share, diluted | — | -0.76—— | -0.16—— | -0.13—— | — | -0.13—— | -0.03—— | -0.25—— | — | -0.32—— | -0.33—— | -0.24—— | — | |
| Shares, weighted average (basic) | 58+3.5%— | 58+3.5%— | 58+3.5%— | 57+3.4%— | — | 56+4.0%— | 56+3.8%— | 55+3.5%— | — | 54—— | 54—— | 54—— | — | |
| Shares, weighted average (diluted) | 58+3.5%— | 58+3.5%— | 58+3.5%— | 57+3.4%— | — | 56+4.0%— | 56+3.8%— | 55+3.5%— | — | 54—— | 54—— | 54—— | — | |
| Balance sheet | ||||||||||||||
| Cash and cash equivalents | 108—98.1% | 108+122%98.1% | 51+62.8%96.2% | 56+14.8%95.1% | 40−23.9%58.4% | 49−36.3%89.7% | 31−50.9%50.2% | 49−40.6%62.9% | 53−30.7%47.8% | 76—56.4% | 64—42.4% | 82—49.1% | 76—41.9% | |
| Other current assets | 0.0—0.0% | 0.0−99.0%0.0% | 0.0−98.1%0.0% | 1.4−7.0%2.4% | 0.0r1.6−98.5%0.0% | 1.2−39.3%2.3% | 1.3−59.5%2.1% | 1.5−57.8%2.0% | 1.9−54.3%1.7% | 2.1—1.5% | 3.2—2.1% | 3.7—2.2% | 4.2—2.3% | |
| Current assets | 109—99.3% | 109+109%99.3% | 52−13.2%97.8% | 58−22.9%97.6% | 67−37.3%97.6% | 52−60.2%96.6% | 59−51.4%95.6% | 75−46.7%96.1% | 107−18.2%97.0% | 132—97.4% | 122—81.5% | 140—83.6% | 131—71.9% | |
| Property, plant and equipment | — | — | — | — | — | — | — | — | 0−100%0.0% | 0—0.0% | 0—0.0% | 0.0—0.0% | 0.0—0.0% | |
| Right-of-use (leased) assets | 0.8—0.7% | 0.8−46.8%0.7% | 1.0−59.9%2.0% | 1.3−55.8%2.1% | 1.5−52.5%2.1% | 1.5r1.7−55.6%2.8% | 2.6−29.6%4.1% | 2.8−27.2%3.7% | 3.1−25.1%2.8% | 3.4—2.5% | 3.6—2.4% | 3.9—2.3% | 4.2—2.3% | |
| Total assets | 110—100% | 110+103%100% | 53−15.1%100% | 59−24.0%100% | 69−37.7%100% | 54−59.9%100% | 62−58.6%100% | 78−53.7%100% | 111−39.4%100% | 135—100% | 150—100% | 168—100% | 182—100% | |
| Accounts payable | 0.4—0.4% | 0.4−70.5%0.4% | 0.2−80.1%0.3% | 0.2−87.7%0.4% | 0.7−90.5%1.0% | 1.4−77.1%2.6% | 0.8−71.1%1.3% | 1.8−42.4%2.3% | 7.3+430%6.6% | 6.1—4.5% | 2.7—1.8% | 3.1—1.8% | 1.4—0.8% | |
| Current liabilities | 57—51.8% | 57+317%51.8% | 8.4−43.6%16.0% | 5.5−81.2%9.3% | 8.9−81.9%12.9% | 14−72.2%25.2% | 15−67.2%24.1% | 29−30.3%37.5% | 49+32.1%44.4% | 49—36.3% | 46—30.4% | 42—24.9% | 37—20.4% | |
| Lease liabilities (non-current) | 0—0.0% | 0−100%0.0% | 0.0−97.6%0.1% | 0.5−76.6%0.9% | 0.9−63.2%1.4% | 1.5−49.6%2.7% | 1.8−44.8%2.9% | 2.2−38.5%2.8% | 2.6−33.3%2.3% | 2.9—2.1% | 3.2—2.1% | 3.5—2.1% | 3.8—2.1% | |
| Total liabilities | 109—99.3% | 109+295%99.3% | 8.6−70.8%16.2% | 6.1−86.1%10.3% | 9.9−84.6%14.4% | 28−60.3%51.1% | 29−57.8%47.2% | 44−38.6%56.5% | 64−14.7%58.3% | 70—51.5% | 69—46.3% | 71—42.6% | 75—41.4% | |
| Retained earnings | −512—−465% | −512—−465% | −468—−887% | −458—−776% | −451—−654% | −483—−891% | −475—−765% | −474—−609% | −460—−416% | −439—−325% | −422—−281% | −404—−241% | −391—−214% | |
| Shareholders' equity | 0.8—0.7% | 0.8−97.1%0.7% | 44+34.7%83.8% | 53+56.5%89.7% | 59+28.0%85.6% | 26−59.6%48.9% | 33−59.2%52.8% | 34−64.9%43.5% | 46−56.9%41.7% | 66—48.5% | 81—53.7% | 96—57.4% | 107—58.6% | |
| Total liabilities and equity | 110—100% | 110+103%100% | 53−15.1%100% | 59−24.0%100% | 69−37.7%100% | 54−59.9%100% | 62−58.6%100% | 78−53.7%100% | 111−39.4%100% | 135—100% | 150—100% | 168—100% | 182—100% | |
| Shares outstanding | 58—— | 58+3.4%— | 58+3.5%— | 58+3.6%— | 56+3.3%— | 56+3.7%— | 56+4.0%— | 56+3.8%— | 55+3.0%— | 54—— | 54—— | 54—— | 53—— | |
| Cash-flow statement | ||||||||||||||
| Depreciation and amortization | — | — | — | — | 0*—0.0% | 0*—0.0% | — | — | 0*−100%0.0% | 0*—0.0% | 0.0*—0.0% | 0—0.0% | 0.0*—0.1% | |
| Share-based compensation | 3.8−21.2%9.1% | 0.9−18.4%— | 0.8+15.1%— | 1.1−28.4%432% | 1.0*−33.0%2.4% | 1.0−51.3%19.3% | 0.7−66.2%5.0% | 1.6−23.1%26.5% | 1.5*−24.7%10.0% | 2.2—16.0% | 2.1—20.7% | 2.0—21.8% | 2.0*—2.7% | |
| Cash from operating activities | −40—−97.3% | −43*−345%— | −5.4*—— | 16—6149% | −8.4*—−20.2% | 17*+36.5%320% | −18*—−125% | −4.0−167%−68.1% | −23*—−156% | 13*—94.8% | −19*—−184% | 5.9—64.1% | −17*—−23.8% | |
| Cash from investing activities | — | — | — | — | — | — | — | — | — | — | — | — | 0*—0.0% | |
| Shares issued | — | — | — | — | — | — | — | — | 0*−100%0.0% | — | — | — | 0.0*—0.0% | |
| Cash from financing activities | — | — | — | — | — | — | — | — | 0*−100%0.0% | — | — | — | 0.0*—0.0% | |
| Change in cash | 59—143% | 57*+228%— | −5.4*—— | 16—6149% | −8.4*—−20.2% | 17*+36.5%320% | −18*—−125% | −4.0−167%−68.1% | −23*—−156% | 13*—94.8% | −19*—−184% | 5.9—64.1% | −17*—−23.8% | |
| Report | Worked out | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | |
* Worked out from reported figures: a quarter the company states only within a year-to-date figure (cash flows are reported that way), or the fourth quarter as the fiscal year minus the first nine months.
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
What Spero Therapeutics, Inc. sells: revenue by product line, fiscal 2025#
As the company reports it, in US dollars, with each line's share of total revenue and the change on fiscal 2024. Lines can overlap (a total and its parts), so they are not added up.
Products and services
- Collaboration revenue - related party$47 M70%+74%
- Collaboration revenue$13 M19%+3303%
- Grant Revenue$7 M11%-65%
Source: SEC annual report (XBRL data) · as of Dec 31, 2025
Executive pay at Spero Therapeutics, Inc.#
From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.
| Fiscal year | CEO total pay | Actually paid | Other executives, average | $100 invested |
|---|---|---|---|---|
| 2025Ms. Rajavelu, Mr. Shukla | $2.1 M | $3.3 M | $1.4 M | $12 |
| 2024Mr. Shukla | $2.0 M | $2.2 M | $945 K | $5 |
| 2023Mr. Shukla | $2.4 M | $2.6 M | $1.4 M | $8 |
Source: SEC proxy statement (Form DEF 14A) · as of Dec 31, 2025
Events at Spero Therapeutics, Inc.#
What the company reported to the SEC within four business days (Form 8-K), newest first.
Warning signs in the last three years
- Delisting noticeFiling
Delisting notice 1 · Restructuring 1 · Directors and officers 8 · Material agreement 2 · New debt 1 · Bylaws or fiscal year changed 1 · Shareholder vote 3 · Results announced 13
| Filed | What happened | Filing |
|---|---|---|
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Directors and officers | 8-K | |
| Material agreement | 8-K | |
| Results announced | 8-K | |
| Material agreementNew debt | 8-K | |
| Directors and officersBylaws or fiscal year changedShareholder vote | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Directors and officersShareholder vote | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Delisting notice | 8-K | |
| Directors and officersResults announced | 8-K | |
| Results announced | 8-K | |
| RestructuringResults announced | 8-K | |
| Results announced | 8-K | |
| Directors and officersShareholder vote | 8-K | |
| Results announced | 8-K |
Source: SEC EDGAR, Form 8-K item numbers · as of Nov 12, 2026
Acquisitions and funding#
1 private funding rounds before listing
Private share sales · funding history
Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.
Lobbying by Spero Therapeutics, Inc.#
$70 K spent on lobbying the US Congress and federal agencies in 2022, most often on health issues.
- Health Issues2 reports
Lobbying firms hired in 2022
Forbes-Tate $70 K
| Year | Spending | Own lobbyists | Reports |
|---|---|---|---|
| 2022 | $70 K | — | 2 |
| 2021 | $50 K | — | 1 |
Source: Lobbying Disclosure Act reports (Form LD-2). Filed as “Spero Therapeutics, Inc.”. Reports round to the nearest $10,000, and one of less than $5,000 counts as zero
H-1B hiring at Spero Therapeutics, Inc.#
2 labor condition applications certified in fiscal 2020 for 2 positions, at a median wage of $128 K a year.
| Job title | Positions | Median wage offered |
|---|---|---|
| Bioanalytical and DMPK ManagerBiochemists and Biophysicists | 1 | $129 K |
| Manager, Analytical DevelopmentBiochemists and Biophysicists | 1 | $127 K |
Where: Cambridge, MA 2
Source: US Department of Labor, LCA disclosure data. An application is not a visa: USCIS decides each petition later, and the yearly lottery limits new H-1B visas. Filed as Spero Therapeutics, Inc.
From US state WARN notices and SEC 8-K restructuring filings, newest first.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024 | · | · | · | · | · | · | · | · | · | · | · | · | — |
| 2022 | · | · | · | · | · | · | · | · | · | · | · | · | — |
| Announced | People | Kind | Where | Source |
|---|---|---|---|---|
| 39% of workforce | Restructuring planSEC 8-K | “Item 2.05 Costs Associated with Exit or Disposal Activities On October 29, 2024, the Company announced an update to its strategic priorities and corresponding reduction in workforc…” | Filing | |
| 75% of workforce | Restructuring planSEC 8-K | “In connection with this development, Spero announced that it is undertaking a reduction in its workforce by approximately 75% and a restructuring of its operations to reduce operat…” | Filing |
Source: State WARN notices and SEC 8-K item 2.05
How Spero Therapeutics, Inc. compares in Biotechnology
- Market cap$69 M · higher than 31% of 726
- Revenue$67 M · higher than 63% of 647
- Net margin12.8% · higher than 80% of 408
- Revenue growth39.2% · higher than 70% of 438
- P/E ratio8.0× · lower than 78% of 100
- Price / sales1.0× · lower than 93% of 339
- Price / book1.2× · lower than 76% of 534
- FCF yield-125.1% · higher than 7% of 449
Peer comparison · Biotechnology
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Spero Therapeutics, Inc.🇺🇸 | $69 M | 8.0× | 12.8% | +39.2% |
| Novo Nordisk A/S🇩🇰 | $203.2 B | 13.1× | 33.1% | +10.8% |
| Vertex Pharmaceuticals Incorporated🇺🇸 | $134.3 B | 33.8× | 30.7% | +8.9% |
| Moderna, Inc.🇺🇸 | $90.1 B | — | -110.5% | -39.9% |
| Regeneron Pharmaceuticals, Inc.🇺🇸 | $84.1 B | 17.5× | 28.5% | +1.0% |
| Argenx SE🇳🇱 | $52.8 B | 40.9× | 31.1% | +89.9% |
| CSL Limited🇦🇺 | $51.6 B | — | -16.4% | — |
| Samsung Biologics Co., Ltd.🇰🇷 | $51.5 B | 40.5× | 39.2% | — |
| UCB SA🇧🇪 | $48.6 B | 26.3× | 20.1% | +31.1% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- Regenxbio Inc.$513 M
- Pharmicell Co., Ltd.$514 M
- Pulike Biological Engineering, Inc.$524 M
- Contineum Therapeutics, Inc.$534 M
- Entera Bio Ltd.$543 M
- Arvinas, Inc.$544 M
Sources and freshness
- Market cap:
- Oct 13, 2026
- Annual results:
- For year ending December-2025
- Balance sheet:
- As of December-2025
- Employees:
- As on 2021
- Profile updated:
- Nov 20, 2026
Figures from Market data, SEC filing, value.today research, GLEIF register; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at Spero Therapeutics, Inc.? Verify and update this profile — free
Show Spero Therapeutics, Inc.'s ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.